{
    "clinical_study": {
        "@rank": "16842", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give delavirdine mesylate\n      (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected\n      children and babies. This study also examines how the body processes Rescriptor when taken\n      with 2 NRTIs."
        }, 
        "brief_title": "A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  Plasma HIV-1 levels greater than 10,000 copies/ml."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "15 Years", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": "24", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002210", 
            "org_study_id": "228D", 
            "secondary_id": "0069"
        }, 
        "intervention": {
            "intervention_name": "Delavirdine mesylate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Reverse Transcriptase Inhibitors", 
                "Delavirdine"
            ]
        }, 
        "keyword": [
            "HIV-1", 
            "Drug Therapy, Combination", 
            "Delavirdine", 
            "Reverse Transcriptase Inhibitors"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Peapack", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07977"
                }, 
                "name": "Pharmacia & Upjohn"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study of the Safety, Tolerance, Pharmacokinetics, and Antiviral Effect of Delavirdine Mesylate (Rescriptor), in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1-Infected Neonates, Infants, and Children", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "citation": "Willoughby R, Watson D, Welliver R. Early use of RESCRIPTOR (delavirdine) in children with HIV. 39th Intersci Conf Antimicrob Agents Chemother. 1999 Sept 26-29 (abstract no 1995)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002210"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pharmacia and Upjohn", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1998"
    }, 
    "geocoordinates": {
        "Pharmacia & Upjohn": "40.717 -74.657"
    }
}